Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine against Novel Coronavirus

share with twitter share with LinkedIn share with facebook
share via e-mail
06/01/2020 | 09:41am EDT

CAMBRIDGE - Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first participants in each age cohort have been dosed in the Company's Phase 2 study of its mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).

This Phase 2 study, being conducted by Moderna under its own Investigational New Drug (IND) application, will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. The Company intends to enroll 600 healthy participants across two cohorts of adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300). Each participant will be assigned to receive placebo, a 50 g or a 100 g dose at both vaccinations. Participants will be followed through 12 months after the second vaccination. Given the 25 g and 100 g dose levels in the Phase 1 study showed neutralizing antibody titers at or above convalescent sera and were generally well tolerated, the Company has decided not to pursue the 250 g dose level in the Phase 2 study.

On May 6, the U.S. Food and Drug Administration (FDA) completed its review of the Company's Investigational New Drug (IND) application for mRNA-1273 and on May 12, the FDA granted it Fast Track designation. On May 18, Moderna announced initial data from the Phase 1 study of mRNA-1273 led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The NIH will be submitting the Phase 1 data to a peer-reviewed clinical publication. Moderna anticipates collaborating with NIAID to implement the Phase 3 study. The dose for the Phase 3 study is expected to be between 25 -microg and 100 -microg and expects Phase 3 trial initiation in July, subject to finalization of the clinical trial protocol.

Funding from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), supported the planning for these studies and will also support the late-stage clinical development programs, as well as the scale-up of mRNA-1273 manufacturing both at the Company's facilities and that of its strategic collaborator, Lonza Ltd. A summary of the company's work to date on SARS-CoV-2 can be found here.

About mRNA-1273

mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at NIAID, a part of the NIH. The first clinical batch, which was funded by CEPI, was completed on February 7, 2020 and underwent analytical testing; it was shipped to NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing.

About Moderna's Prophylactic Vaccines Modality

Moderna scientists designed the company's prophylactic vaccines modality to prevent infectious diseases. More than 1,500 participants have been enrolled in Moderna's infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna's proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.

The potential advantages of an mRNA approach to prophylactic vaccines include the ability to combine multiple mRNAs into a single vaccine, rapid discovery to respond to emerging pandemic threats and manufacturing agility derived from the platform nature of mRNA vaccine design and production. Moderna has built a fully integrated manufacturing plant which enables the promise of the technology platform.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past five years.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company's development of a potential vaccine against the novel coronavirus, the potential benefits of mRNA based vaccines, the benefits of Fast Track designation, the parameters and timing of the planned Phase 2 study of mRNA-1273, the parameters of, timing of and planned dosing in the planned Phase 3 study of mRNA-1273, and BARDA funding for clinical studies and manufacturing activities. In some cases, forward-looking statements can be identified by terminology such as 'will,' 'may,' 'should,' 'could', 'expects,' 'intends,' 'plans,' 'aims,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'continue,' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.


Colleen Hussey

Tel: 203-470-5620

Email: Colleen.Hussey@modernatx.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MODERNA, INC.
05:43pGlobal stocks rally on vaccine hopes, crude oil gains
05:26pStocks rally on vaccine hopes, crude oil gains
05:11pMODERNA : TSX climbs to highest close since March on COVID-19 vaccine hopes
05:02pConsumer Cos Up After Moderna Vaccine Report -- Consumer Roundup
05:00pHealth Care Up As Moderna, AstraZeneca Rise On Vaccine Optimism -- Health Car..
04:54pWall Street rallies on vaccine bets, Goldman results
04:46pEnergy Up With Oil Futures After Inventory Data, Vaccine Report -- Energy Rou..
04:21pModerna, Waters rise; ASML Holding falls
04:19pWALL STREET STOCK EXCHANGE : U.S. Stocks Finish Higher After Promising Vaccine S..
04:03pMODERNA : Fauci bullish on prospects for U.S. vaccine, not worried about China w..
More news
Financials (USD)
Sales 2020 114 M - -
Net income 2020 -530 M - -
Net cash 2020 1 752 M - -
P/E ratio 2020 -55,8x
Yield 2020 -
Capitalization 31 191 M 31 191 M -
EV / Sales 2019
EV / Sales 2020 259x
Nbr of Employees 850
Free-Float 79,7%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 15
Average target price 91,67 $
Last Close Price 80,22 $
Spread / Highest target 67,0%
Spread / Average Target 14,3%
Spread / Lowest Target -25,2%
EPS Revisions
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.310.12%29 177
LONZA GROUP52.32%42 557